European equities traded in the US as American depositary receipts were little change Monday morning, edging 0.1% to 1,553.79 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and semiconductor company Sequans Communications (SQNS), which advanced 7.5% and 6.2% respectively. They were followed by biotech firm BioNTech (BNTX) and medical device maker EDAP TMS (EDAP), which were up 3.2% and 2.4% respectively.

The decliners from continental Europe were led by biopharmaceutical company Genfit (GNFT) and pharmaceutical company Ascendis Pharma (ASND), which fell 9.1% and 4% respectively. They were followed by biotech company Evaxion (EVAX) and lender Banco Bilbao Vizcaya Argentaria (BBVA), which were down 2.9% and 2.8% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and NuCana (NCNA), which rose 7.5% and 6.7% respectively. They were followed by biotech company Autolus Therapeutics (AUTL) and pharmaceutical company Silence Therapeutics (SLN), which increased 3% and 1.9% respectively.

The decliners from the UK and Ireland were led by tobacco company British American Tobacco (BTI) and alcoholic beverage company Diageo (DEO), which dropped 1.6% and 1.1% respectively. They were followed by hospitality company InterContinental Hotels Group (IHG) and medical device maker Smith & Nephew (SNN), which lost 1% each.